All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Peptimmune Inc., a privately held U.S. biotechnology company, has granted Novartis AG an exclusive option to license its drug candidate for multiple sclerosis, PI-2301. (BioWorld Today)
